Ablatus launches crowdfunding campaign for Luna treatment

Ablatus Creators of Luna, a women-led medical device company, has launched a crowdfunding campaign aimed at raising additional funds for its Luna treatment. Its patented core ablation technology lays the groundwork for a minimally invasive solution in treating uterine fibroids that aims to transform women's health globally.    

Having secured £3 million of funding from investors in an earlier financing round led by Mercia Ventures, Low Carbon Innovation Fund and angel investors, Ablatus Therapeutics is now opening the round to its community and new investors to raise additional financing. This funding aims to develop Luna, providing a ray of hope to millions of women affected by uterine fibroids.

Uterine fibroids remain a vastly underserved global health issue, affecting up to 80% of women by the age of 50. While not always symptomatic, fibroids can cause debilitating pain, heavy menstrual bleeding, abdominal swelling, and complications during pregnancy and labour. These conditions impose a staggering up to $34.4 billion annually in the US alone.

Current treatments, including contraceptive pills and invasive surgery, often fall short of providing a comprehensive and fertility-preserving solution. Many women in the US delay treatment for up to three years to avoid invasive procedures, highlighting the urgent need for solutions. 

Dr. Chung Looi, CEO of Ablatus Therapeutics, said: “Our mission is to enable millions of women access to a safe and cost-effective treatment for uterine fibroids so they can enjoy a better quality of life whilst preserving their fertility. We're inviting members of the public to join us today in this transformative journey by pledging to our crowdfunding campaign. Your contribution will help us complete the development of our pioneering femtech solution for fibroids. Everyone knows someone affected by fibroids; with Luna, we're ensuring that future generations won't have to endure unnecessary suffering.”

Ablatus is a spinout from the Norfolk and Norwich University Hospitals NHS Foundation Trust in the UK. The company is backed by angels and VC investors.